Literature DB >> 33738132

Separation-related rapid nuclear transport of DNA/RNA heteroduplex oligonucleotide: unveiling distinctive intracellular trafficking.

Daisuke Ono1, Ken Asada1, Daishi Yui1, Fumika Sakaue1, Kotaro Yoshioka1, Tetsuya Nagata1, Takanori Yokota1.   

Abstract

DNA/RNA heteroduplex oligonucleotide (HDO), composed of DNA/locked nucleic acid (LNA) antisense oligonucleotide (ASO) and complementary RNA, is a next-generation antisense therapeutic agent. HDO is superior to the parental ASO in delivering to target tissues, and it exerts a more potent gene-silencing effect. In this study, we aimed to elucidate the intracellular trafficking mechanism of HDO-dependent gene silencing. HDO was more preferably transferred to the nucleus after transfection compared to the parental ASO. To determine when and where HDO is separated into the antisense strand (AS) and complementary strand (CS), we performed live-cell time-lapse imaging and fluorescence resonance energy transfer (FRET) assays. These assays demonstrated that HDO had a different intracellular trafficking mechanism than ASO. After endocytosis, HDO was separated in the early endosomes, and both AS and CS were released into the cytosol. AS was more efficiently transported to the nucleus than CS. Separation, endosomal release, and initiation of nuclear transport were a series of time-locked events occurring at a median of 30 s. CS cleavage was associated with efficient nuclear distribution and gene silencing in the nucleus. Understanding the unique intracellular silencing mechanisms of HDO will help us design more efficient drugs and might also provide insight into innate DNA/RNA cellular biology.
© 2020 The Authors.

Entities:  

Keywords:  DNA:RNA hybrids; cytosolic release; endosomal escape

Year:  2020        PMID: 33738132      PMCID: PMC7933600          DOI: 10.1016/j.omtn.2020.11.022

Source DB:  PubMed          Journal:  Mol Ther Nucleic Acids        ISSN: 2162-2531            Impact factor:   8.886


  2 in total

1.  Innovative developments and emerging technologies in RNA therapeutics.

Authors:  François Halloy; Annabelle Biscans; Katherine E Bujold; Alexandre Debacker; Alyssa C Hill; Aurélie Lacroix; Olivia Luige; Roger Strömberg; Linda Sundstrom; Jörg Vogel; Alice Ghidini
Journal:  RNA Biol       Date:  2021-12-31       Impact factor: 4.652

2.  DNA/RNA heteroduplex oligonucleotides: An unanticipated twist in the delivery of ASOs.

Authors:  Ryan L Setten; Steven F Dowdy
Journal:  Mol Ther Nucleic Acids       Date:  2022-07-01       Impact factor: 10.183

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.